Prolonged Benefit From Ipilimumab Correlates With Improved Outcomes From Subsequent Pembrolizumab
Cancer immunology research - United States
doi 10.1158/2326-6066.cir-15-0281
Full Text
Open PDFAbstract
Available in full text
Date
May 13, 2016
Authors
Publisher
American Association for Cancer Research (AACR)